CC
REGN icon

Callan Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Callan Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$218K Sell
344
-68
-17% -$46.8K 0.02% 337
2024
Q4 		$293K Buy
412
+49
+13% +$41.1K 0.02% 258
2024
Q3 		$382K Buy
363
+39
+12% +$43.4K 0.03% 222
2024
Q2 		$341K Buy
324
+21
+7% +$20.4K 0.03% 216
2024
Q1 		$292K Buy
+303
New +$288K 0.03% 212

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Callan Capital's REGN Position: Q1 2025 in Review

Callan Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 17% in Q1 2025, selling an estimated $46.8K and leaving 344 shares worth $218K. The position accounts for 0.02% of the portfolio, ranked #337.

Callan Capital first reported a position in REGN in Q1 2024 and has held it in 5 quarters since. The position peaked at $382K in Q3 2024. 1,291 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Callan Capital held 344 shares of Regeneron Pharmaceuticals worth $218K as of Q1 2025.
  • Callan Capital sold 68 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $46.8K.
  • Regeneron Pharmaceuticals made up 0.02% of Callan Capital's portfolio in Q1 2025, its #337 holding.
  • Callan Capital first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
  • Callan Capital's Regeneron Pharmaceuticals position peaked at $382K in Q3 2024.
  • 1,291 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Callan Capital's 13F filing for Q1 2025, filed 29 Apr 2025.